NCT03710876 · MORE INFO

Limitations, agreements, and source contact

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: At the data cut-off date, treatment with rAd-IFN had not resulted in statistically significant differences from the control group (celecoxib + gemcitabine) in the primary efficacy endpoint (OS) or secondary efficacy endpoints. The study was powered to potentially show statistical significance with 300 patients enrolled. Only 82 patients were screened and 53 were randomised.

point Of Contact

email: elisabet.gramming@ferring.com
organization: Ferring Pharmaceuticals A/S
phone: + 45 88 33 88 34
title: Elisabet Gramming

Complete source fields

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: At the data cut-off date, treatment with rAd-IFN had not resulted in statistically significant differences from the control group (celecoxib + gemcitabine) in the primary efficacy endpoint (OS) or secondary efficacy endpoints. The study was powered to potentially show statistical significance with 300 patients enrolled. Only 82 patients were screened and 53 were randomised.

point Of Contact

email: elisabet.gramming@ferring.com
organization: Ferring Pharmaceuticals A/S
phone: + 45 88 33 88 34
title: Elisabet Gramming

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice